Editas Medicine (EDIT) Stock Analysis & Winston Score

Editas Medicine is a biotechnology company that tries to treat diseases by editing the DNA inside human cells. It uses a technology called CRISPR-Cas9, which acts like molecular scissors to cut and fix broken genes. The company focuses on rare genetic diseases, including certain inherited blindness conditions and blood disorders like sickle cell disease. Editas makes almost no revenue today and funds its research through partnerships with larger pharmaceutical companies and by raising money from investors. It operates primarily in the United States and has a market cap of roughly $300 million, which is small for a biotech company. Its main competitive asset is its licensed access to foundational CRISPR patents, but that position has been challenged by ongoing patent disputes. The biggest risk the company faces is running out of cash before it can get a drug approved and generating real sales — its operating losses are very large relative to its size.